Core Biotherapeutics is developing therapeutics that reprogram the transcription factor networks that drive disease

Transcription factors are the master regulators of the genome, controlling the networks of genes that determine a cell’s function. Dysregulation of these networks can trap cells in pathological states, driving disease progression

The key to reprogramming disease lies in the network

Core Bio identifies the transcription factors with disproportionate control over transcription factor networks driving disease. By targeting the dominant regulators, we aim to reprogram the underlying cellular state, not just modulate individual genes or pathways.

REPROGRAM AI: From network biology to therapeutic design


Our technology integrates single-cell data, network biology, and generative drug design to identify the transcription factors with the greatest functional control over transcription factor networks dysregulated in disease and work to design HyperOligos and small molecule drug candidates to reprogram networks to a healthy state.

A pipeline with broad therapeutic potential

Our technlogy enables to systematically expand the pipeline with new drug candidates across indications where transcription factor dysregulation plays a central role
Our technology enables the systemic expansion of our pipeline with new drug candidates across indications where transcription factor dysregulation plays a central role. We are advancing drug candidates designed to reprogram disease-driving networks, beginning with fatal, chronic and debilitating diseases for which we have identified disproportionally dominant, pathological transcription factor targets safe to block over time

Management Team

Julien Mamet, PhD
Chief Executive Officer
20 years of experience in preclinical and clinical TF drug development and biotech building and financing
David Yeomans, PhD
Chief Scientific Officer
Stanford professor and serial biotech entrepreneur, co-founded and joined Core Bio
Experienced team spanning scientific innovation, clinical development and biotech building with a track record of advancing therapeutic programs from discovery through clinical development for drugs that received commercial approval. Our leadership has spent two decades refining the platform's conceptual framework to target transcription factor networks, computational tools, and drug development capabilities
Bill Martin, MBA
Chief Operating Officer
20 years of biotech operation, financing and transaction expertise, from licensing to M&A
Dina Gonzalez, MBA
Chief Financial Officer
20 years managing the finances of both private and publicly traded biotech companies
25 years of experience at the intersection of biomedical research, software engineering and AI
VP of Computational Biology
Michael Klukinov, MD

Board of Directors

Rick Orr, JD
Chairman
Serial entrepreneur with 30 years experience in biotech growth, financing and strategic transaction
Stan Abel, MBA
Chief Executive OfficerProjenx
Long term C-level biotech executive with track record of success growing and transacting companies
Geoff Meyerson, MBA
Chief Executive Officer Locust Walk
Track record of success in investment banking, venture capital and transactions of all varieties
Julien Mamet, PhD
David Yeomans, PhD
CEO, Core Bio
CSO, Core Bio

Contact

Email: hello@corebiotx.com
Address: 2120 University avenue, Berkeley, 94704, CA, USA